News

NORD Issues Statement on Approval of 21st Century Cures Initiative and Introduction of OPEN Act


 

References

NORD President and CEO Peter L. Saltonstall praised the House Energy and Commerce Committee for its recent unanimous approval of the 21st Century Cures Initiative, which includes broad-ranging provisions to enhance the development and delivery of medical treatments. Mr. Saltonstall also noted the introduction in the Senate of the OPEN Act, which encourages the repurposing of approved drugs for the treatment of life-threatening rare diseases. Read the NORD statement.

Recommended Reading

Panel calls for screening for patients with Fanconi anemia
MDedge Endocrinology
New tool facilitates clinical trial follow-up
MDedge Endocrinology
Controversial technique appeals to women with mitochondrial diseases
MDedge Endocrinology
NORD to honor NIH Director and others at Portraits of Courage Celebration
MDedge Endocrinology
NORD urges Congress to support development of treatments for rare pediatric diseases
MDedge Endocrinology
How to code for cystic fibrosis–related diabetes
MDedge Endocrinology
Cystic fibrosis–related diabetes requires different approach
MDedge Endocrinology
ILC: NAFLD a stealth trigger of hepatocellular carcinoma
MDedge Endocrinology
ASA: Mutation testing aids decision making in thyroid cancer
MDedge Endocrinology
NORD, EURORDIS, and Rare Disease Organizations in 30 Nations Announce an International Rare Diseases Alliance (copy 1)
MDedge Endocrinology